225 related articles for article (PubMed ID: 25888580)
21. The TRPS1 transcription factor: androgenic regulation in prostate cancer and high expression in breast cancer.
Chang GT; Jhamai M; van Weerden WM; Jenster G; Brinkmann AO
Endocr Relat Cancer; 2004 Dec; 11(4):815-22. PubMed ID: 15613454
[TBL] [Abstract][Full Text] [Related]
22. Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.
Madarová J; Lukesová M; Hlobilková A; Riháková P; Murray PG; Student V; Vojtsek B; Kolár Z
Neoplasma; 2001; 48(5):419-24. PubMed ID: 11845989
[TBL] [Abstract][Full Text] [Related]
23. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells.
Tonelli F; Lim KG; Loveridge C; Long J; Pitson SM; Tigyi G; Bittman R; Pyne S; Pyne NJ
Cell Signal; 2010 Oct; 22(10):1536-42. PubMed ID: 20570726
[TBL] [Abstract][Full Text] [Related]
24. The DNA/RNA helicase DHX9 contributes to the transcriptional program of the androgen receptor in prostate cancer.
Chellini L; Pieraccioli M; Sette C; Paronetto MP
J Exp Clin Cancer Res; 2022 May; 41(1):178. PubMed ID: 35590370
[TBL] [Abstract][Full Text] [Related]
25. Androgen stimulated cellular proliferation in the human prostate cancer cell line LNCaP is associated with reduced retinoblastoma protein expression.
Taneja SS; Ha S; Garabedian MJ
J Cell Biochem; 2001; 84(1):188-99. PubMed ID: 11746527
[TBL] [Abstract][Full Text] [Related]
26. A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells.
Wang Y; Kreisberg JI; Bedolla RG; Mikhailova M; deVere White RW; Ghosh PM
Oncogene; 2007 Sep; 26(41):6061-70. PubMed ID: 17420725
[TBL] [Abstract][Full Text] [Related]
27. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
[TBL] [Abstract][Full Text] [Related]
28. Autophagy modulators sensitize prostate epithelial cancer cell lines to TNF-alpha-dependent apoptosis.
Giampietri C; Petrungaro S; Padula F; D'Alessio A; Marini ES; Facchiano A; Filippini A; Ziparo E
Apoptosis; 2012 Nov; 17(11):1210-22. PubMed ID: 22923157
[TBL] [Abstract][Full Text] [Related]
29. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
30. High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.
Xie J; Mølck C; Paquet-Fifield S; Butler L; ; Sloan E; Ventura S; Hollande F
Oncotarget; 2016 Jul; 7(28):44492-44504. PubMed ID: 27283984
[TBL] [Abstract][Full Text] [Related]
31. Dose dependent actions of LCL521 on acid ceramidase and key sphingolipid metabolites.
Bai A; Bielawska A; Rahmaniyan M; Kraveka JM; Bielawski J; Hannun YA
Bioorg Med Chem; 2018 Dec; 26(23-24):6067-6075. PubMed ID: 30448190
[TBL] [Abstract][Full Text] [Related]
32. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
33. Auranofin lethality to prostate cancer includes inhibition of proteasomal deubiquitinases and disrupted androgen receptor signaling.
Liu N; Guo Z; Xia X; Liao Y; Zhang F; Huang C; Liu Y; Deng X; Jiang L; Wang X; Liu J; Huang H
Eur J Pharmacol; 2019 Mar; 846():1-11. PubMed ID: 30639309
[TBL] [Abstract][Full Text] [Related]
34. Benzyldihydroxyoctenone, a novel nonsteroidal antiandrogen, shows differential apoptotic induction in prostate cancer cells in response to their androgen responsiveness.
Suh H; Oh HL; Lee CH
J Microbiol Biotechnol; 2011 May; 21(5):540-4. PubMed ID: 21617354
[TBL] [Abstract][Full Text] [Related]
35. Androgens upregulate Cdc25C protein by inhibiting its proteasomal and lysosomal degradation pathways.
Chou YW; Zhang L; Muniyan S; Ahmad H; Kumar S; Alam SM; Lin MF
PLoS One; 2013; 8(4):e61934. PubMed ID: 23637932
[TBL] [Abstract][Full Text] [Related]
36. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
[TBL] [Abstract][Full Text] [Related]
37. Androgen regulation of the messenger RNA encoding diazepam-binding inhibitor/acyl-CoA-binding protein in the human prostatic adenocarcinoma cell line LNCaP.
Swinnen JV; Esquenet M; Heyns W; Rombauts W; Verhoeven G
Mol Cell Endocrinol; 1994 Sep; 104(2):153-62. PubMed ID: 7527352
[TBL] [Abstract][Full Text] [Related]
38. Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A.
Desiniotis A; Schäfer G; Klocker H; Eder IE
Int J Cancer; 2010 Feb; 126(3):775-89. PubMed ID: 19653278
[TBL] [Abstract][Full Text] [Related]
39. The sphingosine kinase inhibitor 2-(p-hyroxyanilino)-4-(p-chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stress-dependent mechanism.
Tonelli F; Alossaimi M; Williamson L; Tate RJ; Watson DG; Chan E; Bittman R; Pyne NJ; Pyne S
Br J Pharmacol; 2013 Mar; 168(6):1497-505. PubMed ID: 23113536
[TBL] [Abstract][Full Text] [Related]
40. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
Zhao XY; Peehl DM; Navone NM; Feldman D
Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
